


Cardiovascular Medicine 2015 Updates for the Practitioner

MAY 3-7 BOSTON, MA



Under the direction of Samuel Z. Goldhaber, MD Peter Libby, MD Patrick T. O'Gara, MD

- > Diagnosis and treatment of acute coronary syndromes
- > Case-based approaches to disease management
- > Emerging technologies in cardiac care
- > Strategies to prevent hospital readmission
- > Aging and end-of-life care

This program is among the highest-rated Harvard Medical School CME courses.

Earn up to 42.00 AMA PRA Category 1 Credits™



Dear Colleague:

On behalf of Brigham and Women's Hospital and Harvard Medical School, for the first time in two years, I invite you to attend our special clinical conference: Cardiovascular Medicine 2015: Updates for Practitioners.

Cardiologists, internists, vascular specialists, hematologists, family practitioners, pharmacists, PAs, and NPs can rely on this program for critical updates and practical education. Past participants will be the first to say that they put this new information to immediate and practical use. This prompt applicability ensures your patients will receive the highest, most up-to-date quality of care and achieve the best possible outcomes. Our curriculum focuses on:

- Acute coronary syndromes
- Advanced heart failure
- Atherosclerosis and inflammation
- Atrial fibrillation
- Cardiomyopathy

- Congenital heart disease
- Pulmonary embolism and pulmonary hypertension
- Thrombosis
- Valvular heart disease
- Vascular medicine

View the complete agenda in this brochure. You'll see that our faculty members, who have won multiple teaching awards, have worked hard to develop a program well suited for cardiovascular medicine specialists as well as generalists and specialists in other fields who care for patients with cardiovascular conditions.

The curriculum also focuses on timely issues and recent advances in areas such as:

- Stroke prevention
- Newly available devices and procedures in the cardiac cath lab and electrophysiology lab
- Preventive cardiology
- Antithrombotics and antiplatelet agents

With so many rapid advances in cardiovascular medicine, it is critically important to ensure your knowledge is complete and up to date. Our program offers new and returning attendees the opportunity to do this.

Offered only once every two years, this course often sells out, so we encourage you to review the complete agenda in this brochure and register as early as possible.

I look forward to seeing and engaging with you.

Best regards.

Sincerely yours,



Samuel Z. Goldhaber, MD
Course Director
Professor of Medicine, Harvard Medical School
Director, Thrombosis Research Group
Senior Staff Cardiologist, Brigham and Women's Hospital

REASONS TO ATTEND

- New guidelines and practice recommendations for lipid therapy
- New findings from megatrials of anti-inflammatory drugs to prevent heart attack and stroke
- Recommendations for avoiding bleeding from "triple therapy"
- Recent advances in patent foramen ovale management
- Best practices for managing advanced heart failure: artificial heart, "bridge to cure," stem cell therapy
- Comprehensive transcatheter aortic valve replacement and mitral valve disease management
- Improving outcomes for patients with stroke prevention in atrial fibrillation using scoring systems, biomarkers, and genetics
- Drug dosing for patients with chronic thromboembolic pulmonary hypertension
- New therapeutic approaches to device therapy to occlude the left atrial appendage and prevent stroke
- New techniques to address massive and submassive pulmonary embolism — new devices, new drugs
- Advances in managing "ventricular tachycardia storm"
- Incorporation of ECMO, ventricular assist devices, and cooling into cardiac resuscitation protocols

Course Overview

Learning Objectives

Upon completion of this course, participants will be able to:

- Integrate state-of-the-art cardiovascular advances into practice.
- Develop strategies to counsel cardiovascular patients and their families on end-of-life care.
- Determine appropriate management of venous thromboembolism and atrial fibrillation, including drug therapy and surgical interventions.
- Utilize new drugs and treatments that are available for cardiovascular conditions.
- Apply the most recent guidelines in practice when appropriate.

Who Attends

- Cardiologists
- Internists
- · Vascular medicine specialists
- · Family medicine practitioners
- · Interventional cardiologists
- Geriatricians
- Hematologists
- · Nurse practitioners

- · Physician assistants
- Electrophysiologists
- Hospitalists
- Pharmacists
- Anesthesiologists
- Pathologists
- Emergency medicine physicians

VENUE

The Fairmont Copley Plaza 138 St. James Avenue Boston, Massachusetts +1 617-267-5300

ACCOMMODATIONS and TRAVEL

A limited number of rooms have been reserved at The Fairmont Copley Plaza Hotel until April 10, 2015. Please specify that you are enrolled in this course to receive a reduced room rate. Hotel arrangements can also be made online at Cardiovascular.HMSCME.com.

Please do not purchase non-refundable ticket(s) until you have received an email from our office confirming your paid registration.

INQUIRIES

Call 617-384-8600 Mon-Fri 9am – 5pm EST. Send e-mail to HMS-CME@hms.harvard.edu.

PAYMENT, CONFIRMATION, and REFUND POLICY

Payment via credit card (VISA, MasterCard, or American Express) or check only. Telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS-DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used to send you critical information, such as your registration confirmation, course evaluation, and certificate of participation.

Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. No refund will be issued should cancellation occur less than two weeks prior. "No shows" are subject to the full course fee and no refunds will be issued once the conference has started.

Harvard Medical School Faculty

Elliott M. Antman, MD Joshua A. Beckman, MD, MS Deepak L. Bhatt, MD, MPH Ron Blankstein, MD Marc P. Bonaca, MD, MPH Eugene Braunwald, MD John G. Byrne, MD Enrico Cagliero, MD Christopher P. Cannon, MD Susan Cheng, MD Mark A. Creager, MD Kevin J. Croce, MD Akshay Desai, MD, MPH Elazer Edelman, MD Laurence Epstein, MD Samuel Z. Goldhaber, MD Karen E. Joynt, MD, MPH Scott Kinlay, MBBS, PhD Michael J. Landzberg, MD Richard T. Lee, MD Peter Libby, MD Leonard S. Lilly, MD Joseph Loscalzo, MD, PhD Laura Mauri, MD, MS

Jessica L. Mega, MD Mandeep R. Mehra, MD David A. Morrow, MD Javid J. Moslehi, MD Jane Newburger, MD Anju Nohria, MD Patrick O'Gara, MD Marc A. Pfeffer, MD, PhD Gregory Piazza, MD, MS Jorge Plutzky, MD Donna Polk, MD, MPH Susan Redline, MD, MPH Paul M. Ridker, MD, MPH Christian T. Ruff, MD, MPH Marc S. Sabatine, MD, MPH Arthur Sasahara, MD Benjamin M. Scirica, MD Scott D. Solomon, MD Michael L. Steigner, MD Lynne W. Stevenson, MD William G. Stevenson, MD Garrick C. Stewart, MD Aaron B. Waxman, MD

Guest Faculty

Gary Balady, MD

Professor of Medicine, Boston University School of Medicine

James Fang, MD

Professor of Medicine, University of Utah

Philip J. Podrid, MD

Professor of Medicine, Boston University School of Medicine

ACCREDITATION

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 42.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 42.00 ECMEC® Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

This Live activity, Cardiovascular Medicine 2015: Updates for the Practitioner, with a beginning date of 05/03/2015, has been reviewed and is acceptable for up to 42.00 Prescribed credits by the **American Academy of Family Physicians**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACGME COMPETENCIES

This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies: patient care, medical knowledge, interpersonal and communication skills, professionalism, and systems-based practice.

ATHEROSCLEROSS, INFLAMMATION, THROMBOSIS, AND RISK FACTORS Session Co-Chairs: Samuel Z. Goldhaber, MD and Patrick O'Gara, MD 8:15 am – 8:50 am Update on the Pathophysiology of Acute Myocardial Infarction Peter Libby, MD 8:50 am – 9:00 am Discussion, Q&A 9:00 am – 9:35 am Discussion, Q&A Patent Foramen Ovale: Stroke and Migraine Risk, and Edification, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A Patent Foramen Ovale: Stroke and Migraine Risk, and Edification, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A Patent Foramen Ovale: Stroke and Migraine Risk, and Edification, Anticoaguisation, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A Patent Foramen Ovale: Stroke and Migraine Risk, and Edification, Anticoaguisation, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A Patent Foramen Ovale: Stroke and Migraine Risk, and Edification, Anticoaguisation, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A Potent Foramen Ovale: Stroke and Migraine Risk, and Edification, Anticoaguisation, or Mechanical Closure Michael J. Landzberg, MD Discussion, Q&A 10:20 am – 10:30 am Discussion, Q&A Discussion, Q&A 10:55 am – 10:55 am Discussion, Q&A 10:05 am – 10:15 am Discussion, Q&A 10:05 am – 10:15 am Discussion, Q&A 10:05 am – 10:15 am Discussion, Q&A 10:04 am – 11:15 am Heyde's Syndrome: Bedside-to-Bench Pathophysioli in Patients with Aortic Stenosis and Gastrointestinal Bleeding Joseph Loscator, MD, PhD Discussion, Q&A 11:15 am – 11:25 am Discussion, Q&A 11:25 am – 12:20 pm Advanced Heart Failure: Principal Management Stression Chair: Peter Libby, MD Advanced Heart Failure: Principal Management Stression Chair: Mandeep R. Mehra, MD Discussion, Q&A 12:45 pm – 2:35 pm Discussion, Q&A 12:45 pm – 2:35 pm					
Samuel Z. Goldmater, Micro Peter Libby, MD Particle Circuits Provided the Australia with Congenital Members (Particle Circuits Samuel Z. Goldmater, March and Particle Circuits Samuel Z. Goldmater, March and Particle Circuits Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Co-Chains: Samuel Z. Goldmater, March and Particle Circuits Session Chains: Particle Session Chai	7:45 am – 8:00 am	5	• • • • • • • • • • • • • • • • • • • •		
Session Co-Chairs: Samare 2. Goldnaber, MD and Patrick O'Cars, MD	8:00 am – 8:15 am	Samuel Z. Goldhaber, MD; Peter Libby, MD;	8:00 am – 8:35 am	Vexing Problem: Novel Management Strategies	
8.15 am – 8.50 am 9.00 am – 9.00 am 9.00 am – 9.00 am 9.00 am – 9.00 am 9.00 bicussion, QAA 9.00 am – 9.00 am 9.00 bicussion, QAA 9.00 bicussion,			8:35 am – 8:45 am		
250 am - 9.00 am		Update on the Pathophysiology of Acute Myocardial		Patent Foramen Ovale: Stroke and Migraine Risk, and Evidence-Based Trials Supporting Aspirin,	
Attroctriomboois Paul M. Ridicky, MD, MPH 9.53 am - 9.45 am 1052 am - 10.20 am 1052 am - 10.20 am 1052 am - 10.20 am 1053 am - 10.20 am 1053 am - 10.30 am 1055 am - 11.30 am 1055 am - 10.30 am 1055 am - 11.30 am 1055 am - 10.30 am 1050	8:50 am – 9:00 am	Discussion, Q&A			
Signam - 9-45 cm Dispulsion		Atherothrombosis Paul M. Ridker, MD, MPH			
Joseph Putzky, MD				Diagnosis, and Emerging Therapies	
10:55 am - 10:55 am Coffe Break Preventive Cardiology: Consensus and Controversy at the Crossroads Donna Polk, MM, MPH 11:30 am - 11:40 am Discussion, O&A THOMAS W, SMITH, MD MEMORIAL LECTURE Session Chair Peter Libby, MD 11:40 am - 12:30 pm 12:30 pm - 12:40 pm 12:30 pm - 12:40 pm 12:30 pm - 12:40 pm 13:50 pm 12:30 pm - 12:40 pm 13:50 pm 13:50 pm 14:40 pm - 15:50 pm 15:50 pm - 2:30 pm 16:50 pm - 2:30 pm 17:50 pm 18:50 pm - 2:30 pm 18:50 pm - 2:3	9:45 am – 10:20 am		10:05 am – 10:15 am		
10.55 am – 11:30 am 11:30 am 11:40 am 1			10:15 am – 10:40 am	Coffee Break	
10:25 m - 11:30 am - 11:40 am bic Corsono, GA THOMAS W. SMITH, MD MEMORIAL LECTURE Session Chair: Peter Libby, MD 11:40 am - 12:30 pm Jodate on Advanced Heart Failure James Fang, MD 11:40 am - 12:30 pm Jodate on Advanced Heart Failure James Fang, MD 12:30 pm - 12:40 pm Discussion, GAA 12:40 pm - 12:50 pm Undate on Advanced Heart Failure James Fang, MD 13:55 pm - 2:30 pm Mittal Valve Discussion, GAA 14:40 pm - 12:50 pm Discussion, GAA 15:55 pm - 2:30 pm Mittal Valve Discussion, GAA 15:55 pm - 2:30 pm Mittal Valve Discussion, GAA 16:56 pm - 3:15 pm Josepak L Bhatt, MD, MPH 16:57 pm - 2:40 pm Discussion, GAA 17:58 pm - 2:40 pm Discussion, GAA 18:59 pm - 3:25 pm Discussion, GAA 18:50 pm - 3:30 pm Discussion, GAA 18:50 pm - 5:15 p			FEATURED PRESEN	TATION: DEPARTMENT OF MEDICINE CHAIR'S LECTURE	
11:10 am − 11:40 am Discussion, QAA Discuss	10:55 am – 11:30 am	the Crossroads	Session Chair: Peter Libby, MD		
11:40 am - 12:30 pm 12:30 pm - 12:40 pm 12:30 pm - 12:40 pm 12:40 pm - 155 pm 12:40 pm - 12:40 pm 13:55 pm - 2:30 pm 14:40 pm - 12:40 pm 15:55 pm - 2:30 pm 15:55 pm - 2:30 pm 16:55 pm - 2:40 pm 16:55 pm - 2:40 pm 17:55 pm - 2:40 pm 17:55 pm - 2:40 pm 18:40 pm - 2:40		Discussion, Q&A	10.40 am – 11.15 am	in Patients with Aortic Stenosis and Gastrointestinal	
11:40 am - 12:30 pm 12:40 pm - 12:40 pm 12:40 pm - 1:55 pm 12:40 pm - 1:55 pm 12:40 pm - 1:55 pm 13:55 pm - 2:30 pm 13:55 pm - 2:35 pm 13:55 pm -	THO		11:15 am – 11:25 am	Discussion, Q&A	
12:30 pm - 12:40 pm 12:40 pm - 1:55 pm ValVULAR HEART DISEASE SYMPOSIUM Session Chair: Deepak L. Bhatt, MD, MPH 1:55 pm - 2:30 pm Mitral Valve Disease: Hemodynamics, Clinical Assessment, and Guidelines Petrick O'Gara, MD 1:20 pm - 12:10 pm Discussion, QAA 1:240 pm - 3:15 pm Discussion, QAA 1:25 pm - 2:30 pm Discussion, QAA 1:25 pm - 2:30 pm Discussion, QAA 1:25 pm - 12:50 pm Discussion, QAA 1:25 pm - 2:30 pm Discussion, QAA 1:25 pm - 2:30 pm Discussion, QAA 1:25 pm - 2:35 pm Discussion, QAA 1:25 pm - 2:35 pm Discussion, QAA 2:30 pm - 4:10 pm Discussion, QAA 1:00 pm - 5:05 pm Discussion, QAA 1:00 pm - 6:00 pm Discussion, QAA 1:00 pm - 6:	11:40 am – 12:30 pm	Update on Advanced Heart Failure	ADVANCED H		
VALVULAR HEART DISEASE SYMPOSIUM Session Chair: Deepak L. Bhatt, MD, MPH 1:55 pm -2:30 pm Mitral Valve Disease: Hemodynamics, Clinical Assessment, and Quidelines Patrick O'Gara, MD Discussion, Q&A 2:40 pm -3:15 pm Discussion, Q&A 2:40 pm -3:15 pm Discussion, Q&A 3:25 pm -4:00 pm Discussion, Q&A 4:10 pm -4:10 pm Discussion, Q&A 4:10 pm -5:05 pm Session C-Chairs: Laurence Epstein, MD and William G. Stevenson, MD Session C-Chairs: Laurence Epstein, MD and William G. Stevenson, MD Sits pm -5:05 pm Discussion, Q&A 3:50 pm -5:05 pm Discussion, Q&A 4:50 pm -5:05 pm Discussion, Q&A 5:15 pm -5:50 pm Discussion, Q&A 5:15 pm -6:00 pm Discussion, Q&A 6:00 pm -6:35 pm Preserved Epstein, MD and Vallation Duarence Epstein, MD Discussion, Q&A 6:00 pm -6:35 pm Preserved Epstein, MD Discussion, Q&A 6:00 pm -6:35 pm Preserved Epstein, MD Discussion, Q&A 6:00 pm -6:35 pm Discussion, Q&A 6:00 pm -6:35 pm Discussion, Q&A 6:00 pm -6:00 pm Discussion, Q&A 6:00 pm -6:00 pm Discussion, Q&A 6:00 pm -6	12:30 pm – 12:40 pm	•	11:25 am – 12:00 pm	Advanced Heart Failure: Principal Management	
Session Chair: Deepak L. Bhatt, MD, MPH	12:40 pm – 1:55 pm	Lunch			
1:55 pm - 2:30 pm Mitral Valve Disease: Hemodynamics, Clinical Assessment, and Guidelines Patrick O'Gara, MD 2:30 pm - 2:40 pm Discussion, Q&A 2:40 pm - 3:15 pm Transcatheter Aortic Valve Replacement Deepak L. Bhatt, MD, MPH 3:25 pm - 3:25 pm Discussion, Q&A 3:25 pm - 4:00 pm Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD 4:00 pm - 4:10 pm Discussion, Q&A 2:35 pm - 4:30 pm Break for Snacks ELECTROPHYSIOLOGY: STATE OF THE ART Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD 4:30 pm - 5:05 pm Stroke Prevention in Atrial Fibrillation: Epidemiology and Risk Assessment, Including Soring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH 5:05 pm - 5:15 pm Discussion, Q&A 5:15 pm - 5:50 pm Stroke Prevention in Atrial Fibrillation: Warfarin, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD 6:35 pm - 6:45 pm Discussion, Q&A 6:45 pm - 7:20 pm Preserved Tiperind Representation of Control of Management William G. Stevenson and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 6:45 pm - 7:20 pm Preserved Tiperind Representation of Cardiac Regeneration and Reversal of Heart Failure Representation Devices, and Ablation Laurence Epstein, MD 6:45 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:45 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:45 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:45 pm - 5:50 pm Discussion, Q&A 6:46 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:47 pm - 6:45 pm Discussion, Q&A 6:48 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:48 pm - 7:20 pm Preserved Tiperind Representation Discussion, Q&A 6:49 pm - 6:45 pm Discussion, Q&A 6:49 pm - 6:45 pm Discussion, Q&A 6:50 pm - 6:45 pm Preserved Tiperind Representation Discussion, Q&A 6:50 pm - 6:45 pm Preserved Tiperind Representat			12:00 pm – 12:10 pm	•	
Assessment, and Quidelines Patrick O'Gara, MD Discussion, Q&A 2:40 pm 3:15 pm Transcatheter Aortic Valve Replacement Deepak L. Bhatt, MD, MPH 3:15 pm -3:25 pm Discussion, Q&A 12:45 pm -12:55 pm Discussion, Q&A 12:45 pm -2:00 pm Lunch Discussion, Q&A 12:45 pm -2:20 pm Discussion, Q&A 12:45 pm -2:25 pm Duscussion, Q&A 12:45 pm -2:35 pm Duscussion, Q&A 12:45 pm -2:25 pm Duscussion, Q&A 12:45 pm -2:55 pm Duscussion	S	ession Chair: Deepak L. Bhatt, MD, MPH	12:10 pm – 12:45 pm		
2:30 pm - 2:40 pm 3:15 pm Transcatheter Aortic Valve Replacement Deepak L. Bhatt, MD, MPH 3:15 pm - 3:25 pm Discussion, Q&A 3:25 pm - 4:00 pm Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrme, MD Discussion, Q&A 2:00 pm - 4:10 pm Discussion, Q&A 2:00 pm - 2:35 pm Discussion, Q&A 2:00 pm - 3:20 pm Discussion, Q&A 2:00 pm - 3:20 pm Discussion, Q&A 2:00 pm - 3:30 pm Discussion, Q&A 2:00 pm - 3:00 pm Discussion, Q&A 2:00 pm - 3:00 pm Discussion, Q&A 2:00 pm - 3:00 pm Discussion, Q&A 2:00 pm - 5:10 pm Discussion, Q&A 2:00 pm -	1:55 pm – 2:30 pm	Assessment, and Guidelines			
Deepak L. Bhatt, MD, MPH 3:15 pm -3:25 pm Discussion, Q&A 3:25 pm -4:00 pm Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD Discussion, Q&A 2:35 pm -2:45 pm Discussion, Q&A D	2:30 pm – 2:40 pm		12:45 pm – 12:55 pm	Discussion, Q&A	
3:15 pm - 3:25 pm Discussion, Q&A Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD Sicussion, Q&A 2:35 pm - 2:35 pm Discussion, Q&A 2:35 pm - 2:45 pm Discussion, Q&A 2:35 pm - 3:20 pm Preserved Ejection Fraction Heart Failure: Epidemiol Pathophysiology, Emerging Innovative Management Strategies Scott D. Solomon, MD Strategies Scott D. Solomon, MD Strategies Scott D. Solomon, MD Discussion, Q&A 2:35 pm - 3:30 pm Discussion, Q&A 2:45 pm - 3:20 pm Discussion, Q&A 2:45 pm - 3:30 pm Discussion, Q&A 2:45 pm - 4:15 pm Discussi	2:40 pm – 3:15 pm		12:55 pm – 2:00 pm	Lunch	
3:25 pm - 4:00 pm Integrating Cardiac Surgery and Invasive Cardiology to Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD 4:00 pm - 4:10 pm Discussion, Q&A 4:10 pm - 4:30 pm Break for Snacks ELECTROPHYSIOLOGY: STATE OF THE ART Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD 4:30 pm - 5:05 pm Stroke Prevention in Atrial Fibrillation: Epidemiology and Risk Assessment, Including Scoring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH 5:05 pm - 5:15 pm 5:05 pm - 6:00 pm 6:00 pm - 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antial Arribythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm - 6:45 pm 6:35 pm - 7:20 pm 7:20 pm - 7:30 pm 7:20 pm - 7:30 pm Discussion, Q&A Discussion, Q&A 2:00 pm - 2:35 pm Outpatient Strategies for Preventing Hospital Readmission due to Exacerbations of Congestive He Failure Readmission due to Exacer	3:15 nm = 3:25 nm	•			
Tackle Valvular and Coronary Heart Disease: A Reboot to Optimize Cardiovascular Services John G. Byrne, MD 4:00 pm – 4:10 pm Discussion, Q&A 4:10 pm – 4:30 pm Discussion, Q&A 4:10 pm – 4:30 pm Discussion, Q&A 4:30 pm – 5:05 pm Discussion Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD 4:30 pm – 5:05 pm Discussion, Q&A 4:50 pm – 4:50 pm Discussion, Q&A 5:50 pm – 6:00 pm Discussion, Q&A 5:00 pm – 5:00 pm Discussion, Q&A Dis				•	
4:00 pm - 4:10 pm Discussion, Q&A 4:10 pm - 4:30 pm Break for Snacks ELECTROPHYSIOLOGY, STATE OF THE ART Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD **ELECTROPHYSIOLOGY, STATE OF THE ART Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD **Strategies Scott D. Solomon, MD **Strategies		to Optimize Cardiovascular Services	2:00 pm – 2:35 pm	Readmission due to Exacerbations of Congestive Heart	
ELECTROPHYSIOLOGY: STATE OF THE ART Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD 4:30 pm – 5:05 pm Stroke Prevention in Atrial Fibrillation: Epidemiology and Risk Assessment, Including Scoring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH 5:05 pm – 5:15 pm Stroke Prevention in Atrial Fibrillation: Warfarin, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD Discussion, Q&A 6:00 pm – 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 7:20 pm Tiscussion, Q&A ADJOURN DAY 1 Stroke Prevention in Atrial Fibrillation: Warfarin, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed to Management William G. Stevenson, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session I: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Session II: Case-Based Stroke Prevention in Atrial Fibrillation: Packed Transition to Breakout Ses	4:00 pm – 4:10 pm	Discussion, Q&A	·	Discussion, Q&A	
Session Co-Chairs: Laurence Epstein, MD and William G. Stevenson, MD 4:30 pm - 5:05 pm Stroke Prevention in Atrial Fibrillation: Epidemiology and Risk Assessment, Including Scoring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH 5:05 pm - 5:15 pm Discussion, Q&A 5:15 pm - 5:50 pm Stroke Prevention in Atrial Fibrillation: Warfarin, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD 5:50 pm - 6:00 pm Discussion, Q&A 6:00 pm - 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm - 6:45 pm Discussion, Q&A **Yentricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 7:20 pm - 7:30 pm ADJOURN DAY 1 **Session L. Case-Based Stroke Prevention in Atrial Fibrillation: Part Englance Prevention in Atrial Fibrillation Atrial Fibrillation Case-Based Stroke Prevention in Atrial Fibrillation			2:45 pm – 3:20 pm	Preserved Ejection Fraction Heart Failure: Epidemiology, Pathophysiology, Emerging Innovative Management Strategies Scott D. Solomon, MD.	
Artial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm 6:45 pm – 7:20 pm 7:20 pm – 7:30 pm 7:30 pm ADJOURN DAY 1 Sincke Prevention in Including Scoring Systems, Biomarkers, and Genetics Christian T. Ruff, MD, MPH 4:05 pm – 4:15 pm 5iscussion, Q&A 4:15 pm – 4:50 pm Systemic Arterial Hypertension: Renal Artery Denervation for Resistant Disease Deepak L. Bhatt, MD, MPH Discussion, Q&A 4:50 pm – 5:00 pm Discussion, Q&A 5:00 pm – 5:15 pm Discussion, Q&A 5:00 pm – 5:15 pm Discussion, Q&A Fransition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation			3:20 pm – 3:30 pm	-	
Biomarkers, and Genétics 4:05 pm - 4:15 pm Discussion, Q&A 4:15 pm - 4:50 pm Systemic Arterial Hypertension: Renal Artery Denervation for Resistant Disease Depak L. Bhatt, MD, MPH Denervation for Resistant Disease Depak L. Bhatt,	4:30 pm – 5:05 pm		·		
5:05 pm – 5:15 pm Discussion, Q&A Stroke Prevention in Atrial Fibrillation: Warfarin, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD Discussion, Q&A 5:50 pm – 6:00 pm Discussion, Q&A Artial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Pemergencies: A Case-Based Approach to Management William G. Stevenson, MD 7:20 pm – 7:30 pm Discussion, Q&A ADJOURN DAY 1 Discussion, Q&A STROKE PREVENTION IN ATRIAL FIBRILLATION Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Case-Based Stroke Prevention in Atrial Fibrillation Session II: Case-Based Stroke Prevention in Atrial Fibrillation		Biomarkers, and Genetics	4:05 pm – 4:15 pm	Discussion, Q&A	
Since Prevention in Artial Indicators, Warralms, Antiplatelet Therapy, and Novel Anticoagulants: Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD 5:50 pm – 6:00 pm Discussion, Q&A 6:00 pm – 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Discussion, Q&A 8REAKOUT SESSIONS I/II—VASCULAR MEDICINE AND STROKE PREVENTION IN ATRIAL FIBRILLATION 5:15 pm – 6:05 pm Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD Transition to Breakout Sessions 6:05 pm – 6:15 pm Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Fibrillation Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Fibrillation Session II: Case-Based Stroke Prevention in Atrial Fibrillation Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Fibrillation	5:05 pm – 5:15 pm		4:15 pm – 4:50 pm	Denervation for Resistant Disease	
Where Do We Stand? Has the Dust Settled? Samuel Z. Goldhaber, MD 5:50 pm – 6:00 pm Discussion, Q&A 6:00 pm – 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Discussion, Q&A 6:45 pm – 7:20 pm Wentricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 7:20 pm – 7:30 pm Discussion, Q&A ADJOURN DAY 1 Transition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation	5:15 pm – 5:50 pm		4.50 5.00	•	
5:50 pm – 6:00 pm 6:00 pm – 6:35 pm Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Discussion, Q&A 6:45 pm – 7:20 pm Tizon pm – 7:30 pm Tizon pm — 7:30 pm ADJOURN DAY 1 BREAKOUT SESSIONS I/II – VASCULAR MEDICINE AND STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION Stroke Prevention in Atrial Stroke Prevention in Atrial Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD 6:05 pm – 6:15 pm Transition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation		Where Do We Stand? Has the Dust Settled?	·		
Atrial Fibrillation: Rate versus Rhythm Control, Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Discussion, Q&A 6:45 pm – 7:20 pm Tizon pm – 7:30 pm Tizon pm — 7:30	5:50 pm – 6:00 pm	•	BREAKO	UT SESSIONS I/II—VASCULAR MEDICINE AND	
Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation Laurence Epstein, MD 6:35 pm – 6:45 pm Discussion, Q&A 6:45 pm – 7:20 pm Wentricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 7:20 pm – 7:30 pm ADJOURN DAY 1 Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD 6:05 pm – 6:15 pm Transition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation		Atrial Fibrillation: Rate versus Rhythm Control,			
6:35 pm – 6:45 pm Discussion, Q&A "Ventricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD T:20 pm – 7:30 pm Discussion, Q&A ADJOURN DAY 1 Discussion, Q&A Session II: Case-Based Stroke Prevention in Atrial Fibrillation Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD Transition to Breakout Sessions Session II: Case-Based Stroke Prevention in Atrial Fibrillation Session II: Case-Based Stroke Prevention in Atrial Fibrillation	,	Antiarrhythmic Therapy, Left Atrial Appendage Occlusion Devices, and Ablation	5:15 pm – 6:05 pm		
6:45 pm – 7:20 pm "Ventricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 7:20 pm – 7:30 pm Discussion, Q&A ADJOURN DAY 1 "Ventricular Tachycardia Storm" and Other EP Emergencies: A Case-Based Approach to Management William G. Stevenson, MD 6:05 pm – 6:15 pm Transition to Breakout Sessions Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation	6:35 pm – 6:45 pm	•			
William G. Stevenson, MD 7:20 pm – 7:30 pm Discussion, Q&A 7:30 pm ADJOURN DAY 1 Discussion, Q&A ADJOURN DAY 1 Session I: Rapid-Fire ECG Quiz Philip J. Podrid, MD Session II: Case-Based Stroke Prevention in Atrial Fibrillation		"Ventricular Tachycardia Storm" and Other EP	6:05 pm _ 6:15 pm	Christian T. Ruff, MD, MPH; Samuel Z. Goldhaber, MD	
7:20 pm – 7:30 pm Discussion, Q&A Philip J. Podrid, MD 7:30 pm ADJOURN DAY 1 Session II: Case-Based Stroke Prevention in Atrial Fibrillation		William G. Stevenson, MD	·		
Fibrillation			55 pm 7.00 pm		
Christian I. nun, Ivid, Ivid, Samuel Z. Goldnaber, MD	7:30 pm	ADJUURN DAY 1		Fibrillation	
Program changes/substitutions may be made without notice. 7:05 pm ADJOURN DAY 2	Program changes/substitutions may be made without notice.		7:05 pm		

Day 2: Monday, May 4

DAY 1: Sunday, May 3

Day 3: Tuesday, May 5

THROMBOEMBOLISM, ANTIPLATELET AGENTS, AND ANTITHROMBOTICS

Session Chair: Arthur Sasahara, MD and Patrick O'Gara, MD

8:00 am - 8:50 am Management of Pulmonary Embolism and Deep Vein Thrombosis, Including Pathophysiology, Risk Stratification, Novel Oral Anticoagulants, Thrombolytic Therapy, Pharmacomechanical Therapy in the Cath Lab, Surgical Embolectomy, and Options for Extended **Duration Anticoagulation**

Samuel Z. Goldhaber, MD

8:50 am - 9:00 am Discussion Q&A

9:00 am - 9:35 am **Chronic Venous Insufficiency and Postthrombotic** Syndrome of the Legs: Diagnosis, Classification, Pathophysiology, Guidelines for Management, and

> **Endovascular Laser Therapy** Gregory Piazza, MD, MS

9:35 am - 9:45 am Discussion, Q&A

9:45 am - 10:20 am Heart Failure and Thrombosis: Which Patients Should I

Anticoagulate? Marc A. Pfeffer, MD, PhD

10:20 am - 10:30 am Discussion, Q&A 10:30 am - 10:55 am Coffee Break

VASCULAR MEDICINE - PART 1

Session Chair: Samuel Z. Goldhaber, MD and Gregory Piazza, MD, MS

10:55 am - 11:30 am **Evaluation and Secondary Stroke Prevention after** Transient Ischemic Attack or Nonembolic Ischemic

Stroke Mark A. Creager, MD

Discussion, Q&A 11:30 am - 11:40 am

11:40 am - 12:15 pm **Principles of Preoperative Evaluation, Including Risk**

Prediction, Workup, Prescription of Beta Blockers or Statins, and Management of Postoperative "Troponin Leaks"

Joshua A. Beckman, MD, MS

12:15 pm - 12:25 pm Discussion, Q&A

12:25 pm - 2:00 pm Lunch

PERICARDITIS MULTIMODALITY CASE DISCUSSION

2:00 pm - 2:10 pm Case presentation Samuel Z. Goldhaber, MD

Electrocardiogram, Echocardiogram, and Sequential 2:10 pm - 2:20 pm

Magnetic Resonance Imaging Ron Blankstein, MD

2:20 pm - 2:40 pm **Idiopathic Pericarditis: Choice of Anti-Inflammatory**

Agent(s), Duration of Therapy, Role of Colchicine, and

Tips on Weaning from Prednisone

Leonard S. Lilly, MD

2:40 pm - 2:50 pm Discussion, Q&A

3:25 pm - 3:35 pm

4:10 pm - 4:20 pm

6:25 pm

AGING AND END OF LIFE

Session Chair: Peter Libby, MD

2:50 pm - 3:25 pm Cardiovascular Medicine in the Elderly: Epidemiology,

Pathophysiology, and Special Patient-Based

Considerations Susan Cheng, MD

Discussion, Q&A

Guiding Cardiovascular Patients and Their Families at 3:35 pm - 4:10 pm

the End of Life

Lynne W. Stevenson, MD Discussion, Q&A

4:20 pm - 4:35 pm Transition to Breakout Sessions

BREAKOUT SESSIONS III/IV

4:35 pm - 5:25 pm Session III: Bleeding and Clotting Cases

Gregory Piazza, MD, MS

Session IV: Difficult Dilemmas That My Patients and I

Have Confronted

Patrick O'Gara, MD

5:25 pm - 5:35 pm Transition to Breakout Sessions Session III: Bleeding and Clotting Cases 5:35 pm - 6:25 pm

Gregory Piazza, MD, MS

Session IV: Difficult Dilemmas That My Patients and I

Have Confronted Patrick O'Gara, MD

ADJOURN DAY 3

Day 4: Wednesday, May 6

ACUTE CORONARY SYNDROMES - PART 1

Session Co-Chairs: Marc S. Sabatine, MD, MPH and David A. Morrow, MD

8:00 am - 8:15 am TIMI Group Overview

Marc S. Sabatine, MD, MPH

8:15 am - 8:20 am Discussion, Q&A

ST Segment Elevation Myocardial Infarction, Including 8:20 am - 9:00 am Mechanical Complications, Guideline Updates, and

Novel/Emerging Therapies

Elliott M. Antman, MD

Non-ST Segment Elevation Myocardial Infarction and 9:00 am - 9:40 am

Unstable Angina: Risk Assessment to Determine Which Patients Should Go to the Cath Lab, the Optimal Timing

for Cath, and Guideline Updates

Christopher P. Cannon, MD

9:40 am - 10:00 am Discussion, Q&A for Drs. Antman and Cannon

10:00 am - 10:25 am Coffee Break

10:25 am - 11:00 am Acute Coronary Syndrome: Role (if any) for Genetic

> Profiling and Functional Testing to Select Antiplatelet Therapy, and How to Balance the Possibility of Major Bleeding versus Reduction in Cardiovascular Mortality when Prescribing Long-Term Thrombin Inhibition Therapy to Prevent Recurrent Acute Coronary Syndrome

Jessica L. Mega, MD

11:00 am - 11:10 am Discussion, Q&A

KENNETH L. BAUGHMAN, MD MEMORIAL LECTURE

Session Chair: Patrick O'Gara, MD

11:10 am - 12:00 pm Exercise and Cardiovascular Disease: Observations,

Mechanisms and Clinical Applications

Gary Balady, MD

12:00 pm - 12:10 pm Discussion, Q&A

12:10 pm - 1:20 pm

ACUTE CORONARY SYNDROMES - PART 2

Session Co-Chairs: Marc S. Sabatine, MD, MPH and David A. Morrow, MD

1:20 pm - 1:55 pm Challenges for Cardiac Intensive Care: Cooling

Protocols, Ventilator Settings, Extracorporeal Membrane Oxygenation, Resuscitation Science

Benjamin M. Scirica, MD

Discussion, Q&A

1:55 pm - 2:05 pm

2:05 pm - 2:40 pm Cardiac Biomarkers: Which Should We Order, When Should We Order, and How Should We Integrate High-

Sensitivity Troponin Assays into Clinical Care?

David A. Morrow. MD

2:40 pm - 2:50 pm Discussion, Q&A

2:50 pm - 3:25 pm Can Coronary CT Angiography Accelerate our Triage of Patients with Suspected Acute Coronary Syndrome,

Shorten Emergency Department Visits, Prevent Overnight Hospitalizations, and Help Us Detect Patients with Vulnerable Plaque? Multiple Rapid-Fire Coronary

CT Images

Michael L. Steigner, MD

3:25 pm - 3:35 pm Discussion, Q&A

3:35 pm - 3:50 pm Transition to Breakout Sessions

BREAKOUT SESSIONS V/VI—CASE-BASED CLINICAL CARDIOLOGY

Session V: Cardiac Intensive Care Unit Cases 3:50 pm - 4:40 pm Benjamin M. Scirica, MD

Session VI: Cardio-Oncology Cases Aniu Nohria, MD

4:40 pm - 4:50 pm Transition To Breakout Sessions

4:50 pm - 5:40 pm Session V: Cardiac Intensive Care Unit Cases

Benjamin M. Scirica, MD

Session VI: Cardio-Oncology Cases

Aniu Nohria, MD

5:40 pm **ADJOURN DAY 4**

Day 5: Thursday, May 7

_	w
5	VASCULAR MEDICINE — PART 2 Session Chair: Samuel Z. Goldhaber, MD
8:00 am – 8:35 am	Diseases of the Aorta, Including Screening Guidelines for Abdominal Aortic Aneurysm Patrick O'Gara, MD
8:35 am - 8:45 am	Discussion, Q&A
8:45 am – 9:20 am	"Code Aorta": How to Organize a Strategic Multidisciplinary Response to a Potentially Fatal Vascular Emergency: Initial Results and Rapid-Fire Case Presentations Marc P. Bonaca, MD, MPH
9:20 am – 9:30 am	Discussion, Q&A
9:30 am – 10:05 am	Percutaneous Interventional Therapies for Vascular Diseases: How to Expand the Services of the Cath Lab Beyond Coronary Intervention Scott Kinlay, MBBS, PhD
10:05 am - 10:15 am	Discussion, Q&A
10:15 am – 10:40 am	Coffee Break
F	EUGENE BRAUNWALD, MD LECTURE
	Session Chair: Peter Libby, MD
10:40 am – 11:30 am	Cardiovascular Medicine: Pivotal Innovations and Dissemination of New Findings Eugene Braunwald, MD
11:30 am – 11:40 am	Discussion, Q&A
Session Co-C	CARDIAC CATH LAB Chairs: Laura Mauri, MD, MS and Kevin J. Croce, MD
11:40 am – 12:15 pm	Innovations in Bare Metal, Drug-Eluting, Self-Expanding, and Absorbable Coronary Stents Elazer Edelman, MD
12:15 pm – 12:25 pm	Discussion, Q&A
12:25 pm – 1:10 pm	Lunch
1:10 pm – 1:45 pm	Coronary Stenting: The Dual Antiplatelet Therapy Study (DAPT Study) of Drug-Eluting and Bare Metal Stents: Optimal Duration of Therapy Based Upon Results of a Megatrial Laura Mauri, MD, MS
1:45 pm – 1:55 pm	Discussion, Q&A
1:55 pm – 2:30 pm	Impact of Public Reporting and Outlier Status Identification on Percutaneous Coronary Intervention Case Selection Karen E. Joynt, MD, MPH
2:30 pm - 2:40 pm	Discussion, Q&A
2:40 pm – 3:15 pm	Optical Coherence Tomography, Fractional Flow Reserve, and Emerging Technologies to Inform Decision Making in the Cardiac Cath Lab Kevin J. Croce, MD
3:15 pm – 3:25 pm	Discussion, Q&A
INTERSECTION	OF CARDIOVASCULAR AND INTERNAL MEDICINE Session Chair: Patrick O'Gara, MD
3:25 pm – 4:00 pm	Sleep-Disordered Breathing: Relationship to Heart Failure, Atrial Fibrillation, and Pulmonary Hypertension Susan Redline, MD, MPH
4:00 pm – 4:10 pm	Discussion, Q&A
4:10 pm – 4:45 pm	What Cardiovascular Specialists Need to Know about Diabetes Mellitus Enrico Cagliero, MD
4:45 pm – 4:55 pm	Discussion, Q&A
4:55 pm – 5:00 pm	General Discussion, Wrap-up
5:00 pm	ADJOURN DAY 5

DISCLOSURE POLICY: Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g., planners, faculty, reviewers, and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.



Cardiovascular Medicine 2015 Updates for the Practitioner

May 3-7, 2015 Boston, MA

Course # 352555	Tuition	Register on or before February 28, 2015*			
Physicians	\$1,495	\$1,295 (SAVE \$200)			
Allied Health Professionals and Physicians in Training	\$1,295	\$1,095 (SAVE \$200)			
☐ Check here to purchase printed course materials Note: All course participants will receive the course materials on a flash drive. Check this box to also purchase printed course materials for an additional fee of \$50.	\$50 (optional)	\$50 (optional)			
Your Total	\$	\$			
To register by mail, complete the fields below and include a check (draft on a United States bank) payable to: Harvard Medical School Department of Continuing Education Mail this completed form and your check to: Harvard Medical School Department of Continuing Education P.O. Box 417476 Boston, MA 02241-7476 Harvard Medical School Department of Continuing Education P.O. Box 417476 Boston, MA 02241-7476 Harvard Medical School Department of Continuing Education P.O. Box 417476 Boston, MA 02241-7476					
Please print your name clearly below. All f	fields are required.				
Full Name First Middle Initial					
	Last				
Profession Degree	Degree				
Mailing AddressStreet					
State/Prov Zip Code	Country	City			
Daytime Phone () Fax Number()					
Email Address					
Please note: Your email address is used for critical information, including registration confirman email address that you check daily or frequently.	mation, evaluation, and o	certificate. Please be sure to include			
Physicians, Please Also Complete These F	Required Fields				
Primary Specialty	Board Ce	rtified? Yes No			
Professional School Attended Harvard Medical School DUS Medical Year of Graduation	al School 🔲 Intern	national Medical School			

Payment, Confirmation and Refund Policy: Payment via credit card (VISA, MasterCard or American Express) or check only. Telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. No refund will be issued should cancellation occur less than two weeks prior. "No shows" are subject to the full course fee and no refunds will be issued once the conference has started.

Please do not make non-refundable travel arrangements until you have received an email from HMS DCE confirming your registration.